GlassScriptPhysician profile
Olusola Joseph
NPI 1922470723
$1,837.97
in general payments reported to CMS, 2019-2025
25 companies · $524 in 2025
The $524 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $644 · 2022: $43.90 · 2023: $300 · 2024: $325 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.04 | 2021-2025 | |
| Lilly USA, LLC | $231.28 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $179.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.66 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $122.61 | 2021-2024 | Farxiga |
| Gilead Sciences, INC. | $120.45 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $117.56 | 2021 | |
| Novo Nordisk INC | $92.59 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Shield Therapeutics INC | $88.37 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $75.69 | 2023-2025 | |
| Exact Sciences Corporation | $65.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.47 | 2021 | |
| Dexcom, INC. | $22.93 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $21.11 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $19.98 | 2021 | |
| Glaxosmithkline, LLC. | $18.71 | 2021 | |
| Abbott Laboratories | $17.72 | 2025 | Freestyle Libre 3 |
| Optinose US, INC. | $17.13 | 2021 | |
| Corcept Therapeutics | $16.96 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $16.26 | 2025 | Symbravo |
| Organon LLC | $16.02 | 2024 | |
| Allergan, INC. | $15.46 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.24 | 2021 | |
| Merck Sharp & Dohme LLC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusola Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.